630 filings
Page 13 of 32
4
Dable Habib J
4 Jan 19
ACCELERON PHARMA / Habib J Dable ownership change
6:34pm
4
Dable Habib J
6 Dec 18
ACCELERON PHARMA / Habib J Dable ownership change
4:22pm
8-K
XLRN
Acceleron Pharma Inc
3 Dec 18
Regulation FD Disclosure
8:34am
10-Q
2018 Q3
XLRN
Acceleron Pharma Inc
Quarterly report
30 Oct 18
4:13pm
8-K
XLRN
Acceleron Pharma Inc
30 Oct 18
Acceleron Reports Third Quarter 2018 Operating and Financial Results
4:10pm
SC 13G/A
T. Rowe Price Group Inc.
10 Oct 18
Acceleron Pharma Inc
11:36am
CT ORDER
XLRN
Acceleron Pharma Inc
4 Sep 18
Confidential treatment order
12:00am
4
XLRN
Acceleron Pharma Inc
31 Aug 18
ACCELERON PHARMA / KEVIN F MCLAUGHLIN ownership change
12:00am
10-Q
2018 Q2
XLRN
Acceleron Pharma Inc
Quarterly report
2 Aug 18
4:22pm
8-K
XLRN
Acceleron Pharma Inc
2 Aug 18
Acceleron Reports Second Quarter 2018 Operating and Financial Results
4:15pm
8-K
XLRN
Acceleron Pharma Inc
26 Jul 18
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial
4:30pm
8-K
XLRN
Acceleron Pharma Inc
9 Jul 18
Results showed a significant reduction in transfusion burden compared to placebo
5:01pm
4
Robert K Zeldin
5 Jul 18
ACCELERON PHARMA / Robert K Zeldin ownership change
4:47pm
3
XLRN
Acceleron Pharma Inc
5 Jul 18
ACCELERON PHARMA / Robert K Zeldin ownership change
4:44pm
4
XLRN
Acceleron Pharma Inc
3 Jul 18
ACCELERON PHARMA / KEVIN F MCLAUGHLIN ownership change
2:32pm
8-K
XLRN
Acceleron Pharma Inc
28 Jun 18
Results showed significant improvement in red blood cell transfusion independence compared to placebo
5:09pm
8-K
XLRN
Acceleron Pharma Inc
20 Jun 18
Other Events
4:44pm
8-K
XLRN
Acceleron Pharma Inc
7 Jun 18
Submission of Matters to a Vote of Security Holders
5:24pm
8-K
XLRN
Acceleron Pharma Inc
5 Jun 18
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
4:43pm
4
XLRN
Acceleron Pharma Inc
11 May 18
ACCELERON PHARMA / John D Quisel ownership change
4:59pm